Search results for "inflammation"

showing 10 items of 2662 documents

Mast cell-derived tumour necrosis factor is essential for allergic airway disease

2007

Mast cells are thought to contribute to allergic airway disease. However, the role of mast cell-produced mediators, such as tumour necrosis factor (TNF), for the development of allergic airway disease is unclear. In order to define the role of mast cells in acute allergic airway disease two strains of mast cell-deficient mice (Kit W/Wv and Kit W-sh/W-sh ) were studied. Compared with their wild-type littermates, Kit W/Wv and Kit W-sh/W-sh mice developed significantly lower airway responsiveness to methacholine and less airway inflammation and goblet cell metaplasia, following sensitisation in the absence of adjuvant and airway challenge. Transfer of bone marrow-derived mast cells (BMMCs) fro…

Pulmonary and Respiratory MedicineAllergyPathologymedicine.medical_specialtyNecrosisInflammationMiceMetaplasiamedicineAnimalsMast CellsInflammationMice KnockoutGoblet cellTumor Necrosis Factor-alphabusiness.industryAllergensrespiratory systemmedicine.diseaseMast cellAsthmarespiratory tract diseasesDisease Models Animalmedicine.anatomical_structureImmunologyImmunizationTumor necrosis factor alphaGoblet CellsBronchial Hyperreactivitymedicine.symptomAirwaybusinessEuropean Respiratory Journal
researchProduct

Hypoxia-induced dysfunction of rat diaphragm

2004

Contains fulltext : 47331.pdf (Publisher’s version ) (Closed access) Oxidants may play a role in hypoxia-induced respiratory muscle dysfunction. In the present study we hypothesized that hypoxia-induced impairment in diaphragm contractility is associated with elevated peroxynitrite generation. In addition, we hypothesized that strenuous contractility of the diaphragm increases peroxynitrite formation. In vitro force-frequency relationship, isotonic fatigability, and nitrotyrosine levels were assessed under hypoxic (Po(2) approximately 6.5 kPa) and hyperoxic (Po(2) approximately 88.2 kPa) control conditions and also in the presence of authentic peroxynitrite (60 min), ebselen (60 min), and t…

Pulmonary and Respiratory MedicineAzolesMalemedicine.medical_specialtyPhysiologyDiaphragmAetiology screening and detection [ONCOL 5]In Vitro TechniquesIsoindolesNitric oxideContractilitychemistry.chemical_compoundTranslational research [ONCOL 3]Physiology (medical)Internal medicineOrganoselenium CompoundsPeroxynitrous AcidmedicineRespiratory muscleAnimalsRespiratory systemEnzyme InhibitorsRats WistarHypoxiaHeart lung and circulation [UMCN 2.1]Renal disorder [IGMD 9]omega-N-MethylarginineNitrotyrosineCell BiologyHypoxia (medical)Tissue engineering and pathology [NCMLS 3]musculoskeletal systemRatsPathogenesis and modulation of inflammation [N4i 1]EndocrinologychemistryBiochemistryMuscle FatigueTyrosineRat DiaphragmLipid Peroxidationmedicine.symptomPeroxynitriteMuscle ContractionAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
researchProduct

2014

Background In models of COPD, environmental stressors induce innate immune responses, inflammasome activation and inflammation. However, the interaction between these responses and their role in driving pulmonary inflammation in stable COPD is unknown. Objectives To investigate the activation of innate immunity and inflammasome pathways in the bronchial mucosa and bronchoalveolar lavage (BAL) of patients with stable COPD of different severity and control healthy smokers and non-smokers. Methods Innate immune mediators (interleukin (IL)-6, IL-7, IL-10, IL-27, IL-37, thymic stromal lymphopoietin (TSLP), interferon γ and their receptors, STAT1 and pSTAT1) and inflammasome components (NLRP3, NA…

Pulmonary and Respiratory MedicineCOPDThymic stromal lymphopoietinInnate immune systemmedicine.diagnostic_testbiologybusiness.industryCaspase 1NALP3InflammationInflammasomemedicine.diseaserespiratory tract diseases3. Good healthBronchoalveolar lavageImmunologymedicinebiology.proteinmedicine.symptombusinessmedicine.drugThorax
researchProduct

Phenotypes contribute to treatments.

2017

Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries; however, there are no data regarding clinical phenotypes of these patients in this region. Participation in the Phenotypes of COPD in Central and Eastern Europe (POPE) study was offered to stable patients with COPD in a real-life setting. The primary aim of this study was to assess the prevalence of phenotypes according to predefined criteria. Secondary aims included analysis of differences in symptom load, comorbidities and pharmacological treatment. 3362 patients with COPD were recruited in 10 CEE countries. 63% of the population were nonexacerbators, 20.4% frequ…

Pulmonary and Respiratory MedicineChronic bronchitismedicine.medical_specialtyExacerbation1InflammationDisease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineHumansCOPD030212 general & internal medicineCOPDbusiness.industryOriginal Articlesmedicine.diseasePhenotypeObstructive lung diseaserespiratory tract diseasesPhenotype030228 respiratory systemImmunologymedicine.symptomAirwaybusinessThe European respiratory journal
researchProduct

Epithelial-mesenchymal communication in the pathogenesis of chronic asthma.

2005

Although Th-2-mediated inflammation is a key therapeutic target in asthma, its relationship to altered structure and functions of the airways is largely unknown. In addition to inflammation, asthma is a disorder involving the airway epithelium that is more vulnerable to environmental injury and responds to this by impaired healing. This establishes a chronic wound scenario that is capable of sustaining chronic inflammation as well as remodeling. This response occurs as a consequence of activation of the epithelial-mesenchymal unit, involving reciprocal activities of growth factors belonging to the fibroblast growth factor, epidermal growth factor, and transforming growth factor-beta familie…

Pulmonary and Respiratory MedicineChronic woundInflammationBiologyFibroblast growth factorPathogenesisTh2 CellsEpidermal growth factormedicineHumansGrowth Substancesasthma InflammationAsthmaInflammationWound HealingMesenchymal stem cellModels ImmunologicalEpithelial CellsMuscle SmoothFibroblastsmedicine.diseaseAsthmarespiratory tract diseasesImmunologyChronic DiseaseRespiratory Physiological PhenomenaRespiratory epitheliumCytokinesmedicine.symptom
researchProduct

Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier

2015

Gene therapy, i.e. the delivery and expression of therapeutic genes, holds great promise for congenital and acquired respiratory diseases. Non-viral vectors are less toxic and immunogenic than viral vectors, although they are characterized by lower efficiency. However, they have to overcome many barriers, including inflammatory and immune mediators and cells. The respiratory and airway epithelial cells, the main target of these vectors, are coated with a layer of mucus, which hampers the effective reaching of gene therapy vectors carrying either plasmid DNA or small interfering RNA. This barrier is thicker in many lung diseases, such as cystic fibrosis. This review summarizes the most impor…

Pulmonary and Respiratory MedicineCystic FibrosisGenetic enhancementContext (language use)Gene deliveryVectors in gene therapyPolyethylene GlycolsViral vectorPolyethyleinimine Poly-L-lysine Ethylene glycol Chitosan PAMAM G0 dendrimer N-(1-(23-Dioleyloxy)propyl)-NNNtrimethylammonium chloride 12-Dioleoylphosphatidylethanolamine N-acetylcystein 12-Dioctadecanoyl-sn-glycero-3-phosphoethanolaminemedicineHumansTechnology PharmaceuticalPharmacology (medical)RNA Small InterferingLungExpectorantsInflammationLungbusiness.industryBiochemistry (medical)Gene Transfer TechniquesGenetic TherapyMucusMucusmedicine.anatomical_structureSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoImmunologyNanoparticlesInflammation MediatorsbusinessPlasmidsRespiratory tract
researchProduct

Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease

2005

Current therapy for chronic obstructive pulmonary disease (COPD) fails to alter its relentless progression. This remains a significant challenge and unmet need. A recent advance is the demonstration that treatment with a fixed dose of an inhaled corticosteroid and a long-acting beta2-agonist in COPD improves lung function and quality of life, and reduces exacerbation more effectively than either drug alone. Other improvements include the introduction of tiotropium, a once-daily anticholinergic. In advanced clinical development are other once-daily bronchodilators and combinations of anticholinergic drugs and beta2-agonists. Increased understanding of the pathogenesis of COPD has led to nove…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyExacerbationPhosphodiesterase Inhibitorsmedicine.drug_classmedia_common.quotation_subjectAnti-Inflammatory AgentsPharmacologySystemic inflammationAntioxidantsPathogenesisPulmonary Disease Chronic ObstructiveAdministration InhalationAnticholinergicmedicineHumansProtease InhibitorsIntensive care medicineGlucocorticoidsmedia_commonCOPDInhalationbusiness.industryAntibodies MonoclonalAdrenergic beta-Agonistsmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesDrug developmentQuality of LifeSmoking Cessationmedicine.symptombusinessProceedings of the American Thoracic Society
researchProduct

Lung penetration and patient adherence considerations in the management of asthma: role of extra fine formulations

2013

The mainstay of management in asthma is inhalation therapy at the target site, with direct delivery of the aerosolized drug into the airways to treat inflammation and relieve obstruction. Abundant evidence is available to support the concept that inflammatory and functional changes at the level of the most peripheral airways strongly contribute to the complexity and heterogeneous manifestations of asthma. It is now largely accepted that there is a wide range of clinical phenotypes of the disease, characterized primarily by small airways involvement. Thus, an appropriate diagnostic algorithm cannot exclude biological and functional assessment of the peripheral airways. Similarly, achievement…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyPathologymedia_common.quotation_subjectDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioQuality of life (healthcare)Asthma controlJournal of Asthma and AllergymedicineImmunology and AllergyIntensive care medicinedeviceOriginal Researchmedia_commonAsthmasmall airwaysLungInhalationbusiness.industrySmall airwaysasthmarespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structurequality of lifeinflammationCorrigendumbusinessJournal of Asthma and Allergy
researchProduct

Zur Immunpathogenese des Asthma bronchiale

2000

Allergic asthma is a chronic pulmonary disease associated with bronchoconstriction and inflammation. Recent studies have shown that mediator substances and proinflammatory cytokines produced by mast cells, eosinophils and T-lymphocytes appear to be important for the pathogenesis of asthma. These substances contribute both to the initiation and perpetuation of the disease. In particular, it has been shown that allergic asthma is associated with increased TH2 (IL-4, IL-5, IL-13) cytokine production that causes activation of eosinophils and T-cells and production of chemokines (e.g. eotaxin) by pulmonary fibroblasts. Based on recent advances in our understanding of the immunopathogenesis of as…

Pulmonary and Respiratory MedicineEotaxinChemokinebiologybusiness.industrymedicine.medical_treatmentInflammationImmunoglobulin Emedicine.diseaseProinflammatory cytokineCytokineImmunologybiology.proteinMedicineBronchoconstrictionmedicine.symptombusinessAsthmaPneumologie
researchProduct

Interleukin-2 receptor gene expression by bronchoalveolar lavage lymphocytes in pulmonary sarcoidosis.

1989

Current concepts of the immunopathogenesis of sarcoidosis favor a central role of activated, interleukin-2 (IL-2) producing helper T-cells at sites of inflammation. Normally, activated T-cells release IL-2 and express IL-2 receptors (IL-2R). IL-2R+ cells, however, are not uniformly found in patients with clinically active disease. To determine whether the lack of IL-2R+ cells is caused by a dysregulation of the IL-2R gene or by the mode of T-cell activation in pulmonary sarcoidosis, we quantified IL-2 and IL-2R m-RNA transcripts, IL-2 release, and IL-2R surface protein in peripheral blood lymphocytes of patients with sarcoidosis and normal control subjects before and after in vitro stimulat…

Pulmonary and Respiratory MedicineInterleukin 2AdultLung DiseasesPathologymedicine.medical_specialtySarcoidosisLymphocyteT-LymphocytesInflammationLymphocyte ActivationIn vivomedicineHumansRNA MessengerReceptorLungmedicine.diagnostic_testbusiness.industryReceptors Interleukin-2medicine.diseasemedicine.anatomical_structureBronchoalveolar lavageGene Expression RegulationImmunologyInterleukin-2Sarcoidosismedicine.symptombusinessBronchoalveolar Lavage Fluidmedicine.drugThe American review of respiratory disease
researchProduct